The effect of complement system on viability of mycobacteria (Mycobacterium vaccae and Mycobacterium bovis-BCG, as models) was studied by using 3H-uracil uptake method. The results showed no killing effect on these mycobacteria. Pretreatment of these mycobacteria with antimycobacterial antibodies also did not result in making them susceptible to complement. These observations were confirmed electronmicroscopically where no ultrastructural changes indicative of cell destruction were seen after treatment with complement in the presence and absence of antibody.
Download full-text PDF |
Source |
---|
Antibiotics (Basel)
December 2024
School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore 637551, Singapore.
() infection causes tuberculosis (TB). TB is one of the most intractable infectious diseases, causing over 1.13 million deaths annually.
View Article and Find Full Text PDFBiomolecules
November 2024
Department of Organic Chemistry, Kaunas University of Technology, Radvilėnų pl. 19, 50254 Kaunas, Lithuania.
A series of target 4-substituted-5-(2-(pyridine-2-ylamino)ethyl)-2,4-dihydro-3-1,2,4-triazole-3-thiones and their chloro analogs - were synthesized in a reaction of the selected aldehydes with the corresponding 4-amino-1,2,4-triazole-3-thiones and , which were obtained from 3-(pyridin-2-ylamino)propanoic acid () or 3-((5-chloropyridin-2-yl)amino)propanoic acid (), respectively, with thioacetohydrazide. The antibacterial and antifungal activities of the synthesized hydrazones were screened against the bacteria , , and and the fungi and by agar diffusion and serial dilution methods. 4-Amino-5-(2-((5-chloropyridin-2-yl)amino)ethyl)-2,4-dihydro-3-1,2,4-triazole-3-thione () and 4-(benzylideneamino)-5-(2-(pyridin-2-ylamino)ethyl)-2,4-dihydro-3-1,2,4-triazole-3-thione () were identified as exceptionally active (MIC 0.
View Article and Find Full Text PDFJ Biomol Struct Dyn
December 2024
University School of Basic & Applied Sciences, Guru Gobind Singh Indraprastha University, New Delhi, India.
UDP-N-acetylenolpyruvoylglucosamine reductase ( from has gathered significant pharmaceutical interest as a pivotal target because of its essential role in bacterial viability. This study employed computational methods to screen and assess the inhibitory potential of dicoumarol derivatives against the protein. A diverse set of dicoumarols, sourced from PubChem and Zinc database, is subjected to molecular docking, ADME studies, and MD simulations to elucidate interacting modes and stability.
View Article and Find Full Text PDFN Engl J Med
December 2024
From the Research Division, Instituto Lauro de Souza Lima, Bauru (J.B., P.S.R.), and Fundação de Dermatologia Tropical e Venereologia Alfredo da Matta, Manaus (P.F.B.R.) - both in Brazil; the Department of Health and Human Services, Health Resources and Services Administration, Health Systems Bureau, National Hansen's Disease Program, Laboratory Research Branch, Baton Rouge, LA (L.A., R.T.); Translational Medicine and Early Development Statistics (S.Y.), WAVE Team (Z.A., S.R.C., S.K., D.M., J.A.P., M.W.), Janssen Research and Development, San Diego, CA; Janssen Global Public Health, Janssen Research and Development, Titusville, NJ (N.B., R.D.A.); and Janssen Global Public Health, Janssen Pharmaceutica, Beerse, Belgium (E.E., N.L., B.R.).
Background: Standard multidrug therapy for leprosy may be associated with severe side effects, which add to the stigma and discrimination that affect persons with the disease. In addition, the threat posed by drug-resistant leprosy shows the need for alternative drug combinations and shorter, safer regimens of multidrug therapy.
Methods: In this open-label, proof-of-concept study conducted in Brazil, we assigned patients with previously untreated multibacillary leprosy to receive bedaquiline monotherapy for 8 weeks.
ACS Appl Mater Interfaces
December 2024
Department of Surgery-Otolaryngology Head and Neck Surgery, Basil Hetzel Institute for Translational Health Research, Central Adelaide Local Health Network, Adelaide 5011, Australia.
Nontuberculous mycobacteria (NTM) are among the recalcitrant bacterial strains that cause difficult-to-treat infections for patients with chronic underlying pulmonary conditions. The bacteria's intrinsic resistance to various antibiotics and their ability to infect macrophages enable them to overcome both the host immune response and standard antibiotics. Unconventional approaches to treating NTM-mediated infections are required.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!